Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2003

View Archived Issues

Potential cardiovascular benefits induced by rosiglitazone in diabetes and insulin resistance

Synthetic retinal peptide improves functional activity in diabetic retinopathy

Improved pharmacokinetic and pharmacodynamic profile found for insulin detemir in type 1 diabetes

Pioglitazone improves glucose tolerance and microvascular function in type 2 diabetes

Severe oral mucositis in cancer patients improved by rHuKGF

Remune enters treatment interruption study in HIV-1-infected patients

Phase III Theratope vaccine trial fails to meet primary endpoints

Calpain inhibitors with improved pharmacokinetics and neuroprotective efficacy

New antibacterial tylosin analogues covered by Enanta patent

Gabusectin, a novel antibiotic prepared and tested by Aventis researchers

Adenosine A2A receptor ligands and their use reported by Roche

Novel CRF antagonists for use in anxiety, depression and IBS

Sanofi-Synthelabo claims novel TNF-alpha production inhibitors in recent patent

Lilly reports new series of PPARalpha agonists

Beta-secretase inhibitors identified by Elan and Pharmacia (Pfizer) team

Boston Life Sciences to pursue SPA for phase III study of Altropane

Novuspharma to merge with Cell Therapeutics

Enzon acquires North American license to ATG-Fresenius S

Metvix label extension recommended in Australia

Second phase IIa study for TA-CD in cocaine dependence reports findings

Enrollment completed in phase II/III European trial of Trabio

CARDS Lipitor trial stopped two years early because of significant atorvastatin benefit

Forsteo approved in E.U. for treatment of osteoporosis in postmenopausal women

FDA approves FluMist as first intranasal influenza vaccine

Specific human mast cell tryptase inhibitor blocks collagen production in human lung fibroblasts

New nonestrogenic inhibitors of human steroid sulfatase synthesized at Theramex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...